dulaglutide + lisinopril

**dulaglutide + lisinopril** is a combination of **dulaglutide**, a glucagon-like peptide 1 (GLP-1) receptor agonist used primarily for glycemic control in type 2 diabetes, with **lisinopril**, an angiotensin-converting enzyme (ACE) inhibitor used mainly for hypertension and heart failure. Dulaglutide acts by activating the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing glucagon secretion, and slowing gastric emptying. Lisinopril inhibits the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced aldosterone-mediated sodium retention. While both are frequently co-prescribed (especially in patients with type 2 diabetes and co-existing hypertension), this is not a fixed-dose commercial combination, but a concurrent use of two drugs with complementary mechanisms. There are no known clinically significant pharmacokinetic or pharmacodynamic interactions between dulaglutide and lisinopril[1][3][5][9].